+$247.0
Net Activity
Institutions Holding
5
Popularity Rank
#11765
Avg Weight
0.00%
Total Value
$9.4K
5 institutions currently hold PVCT, with 1 net buyers and 0 net sellers this quarter.
Institutional Moves (Q1 2026)
Significantly Increased
Based on recent trading activity
Net Selling Institutions
0
Net Buying Institutions
1
Top 5 by Value
+$999.0
Total Buy Value
$0.0
Total Sell Value
1
Net Buyers
0
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
Provectus Biopharmaceuticals approved the conversion of $542,500 in accrued directors' fees into Series D-1 Preferred Stock. The conversion price is $2.862 per share, resulting in 189,554 preferred shares that are convertible into 1,895,540 common shares. The move settles outstanding cash compensation owed to board members.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter